Jorge Bermudez
Director/Board Member at Drugs for Neglected Diseases initiative
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Suerie Moon | M | - |
Drugs for Neglected Diseases initiative
 Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | - |
| Marcel Tanner | M | - |
Drugs for Neglected Diseases initiative
Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | - |
| Luis Enrique Pizarro Maqueda | M | - |
Drugs for Neglected Diseases initiative
Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | 2 years |
| Manoel Barral Neto | M | - |
Fundação Oswaldo Cruz
| 34 years |
| John Reeder | M | - |
Drugs for Neglected Diseases initiative
Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | - |
| Noor Hisham Abdullah | M | - |
Drugs for Neglected Diseases initiative
Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | - |
| Joanne Liu | M | - |
Drugs for Neglected Diseases initiative
Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | - |
| Thomas Saugnac | M | - |
Drugs for Neglected Diseases initiative
Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | - |
| Bernhards Ogutu | M | - |
Drugs for Neglected Diseases initiative
Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | - |
| Marie-Paule Kieny | F | 68 |
Drugs for Neglected Diseases initiative
Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | 7 years |
| Alwyn Mwinga | M | - |
Drugs for Neglected Diseases initiative
Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | - |
| Stewart Cole | M | - |
Drugs for Neglected Diseases initiative
Drugs for Neglected Diseases initiative BiotechnologyHealth Technology Drugs for Neglected Diseases initiative provides drug research and development services. It specializes in analyzing the causes of and in developing medicine and treatments for neglected diseases. It specializes in the study of neglected tropical diseases, such as sleeping sickness (Human African Trypanosomiasis), Leishmaniasis, Chagas, malaria, pediatric HIV, and filarial diseases. It develops a research and development portfolio that includes projects from discovery through to post-registration phases. Its focus areas encompass regional disease-specific platform development, technology transfer, and public responsibility and awareness advocacies. The organization was founded in July 2003 and is headquartered in Geneva, Switzerland. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dulce Pugliese de Godoy Bueno | M | 76 |
Federal University of Rio de Janeiro
| 6 years |
| Paulo Sergio Moreira da Fonseca | M | - |
Federal University of Rio de Janeiro
| 6 years |
| Luiz Serafim Spínola Santos | M | 77 |
Federal University of Rio de Janeiro
| 6 years |
| Antônio dos Santos Maciel Neto | M | 66 |
Federal University of Rio de Janeiro
| 4 years |
| Jean-François Rial | M | 61 |
Unitaid
 Unitaid Miscellaneous Commercial ServicesCommercial Services Unitaid operates organization that invests in innovations to prevent, diagnose and treat HIV/AIDS. The company was founded in 2006 and is headquartered in Geneva, Switzerland. | - |
| Peter Dvorsak | M | 74 |
Federal University of Rio de Janeiro
| 4 years |
| Eduardo de Oliveira Rodrigues Filho | M | 69 |
Federal University of Rio de Janeiro
| 2 years |
| Ricardo Schaefer | M | 73 |
Federal University of Rio de Janeiro
| 4 years |
| Alberto Ramy Mansur | M | 75 |
Federal University of Rio de Janeiro
| 4 years |
| Paulo Sérgio Lacerda Beirão | M | - |
Federal University of Rio de Janeiro
| 1 years |
| Luiz Alberto Gaspar Domingues | M | 72 |
Federal University of Rio de Janeiro
| 4 years |
| Gilberto Carvalho Lima | M | 67 |
Federal University of Rio de Janeiro
| 4 years |
| Jorge Ricardo Bittar | M | - |
Federal University of Rio de Janeiro
| 4 years |
| Luis Octávio Carvalho da Motta Veiga | M | 73 |
Federal University of Rio de Janeiro
| 3 years |
| Mario Eisenberger | M | 75 |
Federal University of Rio de Janeiro
| 3 years |
| Oscar Alfredo Salomão Filho | M | 67 |
Federal University of Rio de Janeiro
| 4 years |
| Alexandre Magalhães da Silveira | M | - |
Federal University of Rio de Janeiro
| 4 years |
| Jose Luiz Villar Boardman | M | - |
Federal University of Rio de Janeiro
| 4 years |
| Jerson Kelman | M | 76 |
Federal University of Rio de Janeiro
| 4 years |
| Homero Valle de Menezes Côrtes | M | 76 |
Federal University of Rio de Janeiro
| 4 years |
| Luiz Antonio Moreira Sant'Anna | M | - |
Federal University of Rio de Janeiro
| 4 years |
| Carlos Tadeu da Costa Fraga | M | 66 |
Federal University of Rio de Janeiro
| 4 years |
| Luiz Aranha Corrêa do Lago | M | 73 |
Federal University of Rio de Janeiro
| 4 years |
| José Eduardo de Barros Dutra | M | 67 |
Federal University of Rio de Janeiro
| 4 years |
| Carlos Alberto Pereira de Oliveira | M | 66 |
Federal University of Rio de Janeiro
| 4 years |
| Gabriel Stoliar | M | 70 |
Federal University of Rio de Janeiro
| 4 years |
| Renato da Cruz Gomes | M | 71 |
Federal University of Rio de Janeiro
| 4 years |
| Carlos Geraldo Langoni | M | 79 |
Federal University of Rio de Janeiro
| 4 years |
| Gerd Peter Poppinga | M | 64 |
Federal University of Rio de Janeiro
| 4 years |
| Murilo César Lemos dos Santos Passos | M | 76 |
Federal University of Rio de Janeiro
| 4 years |
| Paulo Carvalho Filho | M | 79 |
Federal University of Rio de Janeiro
| 4 years |
| José Alexandre Scheinkman | M | 76 |
Federal University of Rio de Janeiro
| 4 years |
| Valdison Moreira | M | 67 |
Federal University of Rio de Janeiro
| 4 years |
| Aldo Floris | M | 75 |
Federal University of Rio de Janeiro
| 4 years |
| José Afonso Alves Castanheira | M | 77 |
Federal University of Rio de Janeiro
| 4 years |
| Renan Bergmann | M | 70 |
Federal University of Rio de Janeiro
| 1 years |
| José Jorge de Vasconcelos Lima | M | 79 |
Federal University of Rio de Janeiro
| 1 years |
| Paulo Roberto Vales de Souza | M | 75 |
Federal University of Rio de Janeiro
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Brazil | 38 | 76.00% |
| Switzerland | 12 | 24.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jorge Bermudez
- Personal Network
